Cargando…

Pathology versus molecular genetics: (re)defining the spectrum of Alport syndrome

Next generation sequencing applied to families with glomerular disease has been instrumental in identifying new genes and pathways involved in podocyte homeostasis. Malone et al. performed sequencing on 70 families with FSGS and discovered that 10% had variants in surprising “old” genes, COL4A3 and...

Descripción completa

Detalles Bibliográficos
Autor principal: Miner, Jeffrey H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246419/
https://www.ncbi.nlm.nih.gov/pubmed/25427084
http://dx.doi.org/10.1038/ki.2014.326
_version_ 1782346509696630784
author Miner, Jeffrey H.
author_facet Miner, Jeffrey H.
author_sort Miner, Jeffrey H.
collection PubMed
description Next generation sequencing applied to families with glomerular disease has been instrumental in identifying new genes and pathways involved in podocyte homeostasis. Malone et al. performed sequencing on 70 families with FSGS and discovered that 10% had variants in surprising “old” genes, COL4A3 and COL4A4, which are involved in Alport syndrome and thin basement membrane nephropathy. These data show that a subset of renal manifestations associated with COL4A3 or COL4A4 variants cannot be distinguished from FSGS by clinical data or by histopathology. Thus, a diagnosis of FSGS may sometimes fall within the spectrum of Alport syndrome.
format Online
Article
Text
id pubmed-4246419
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-42464192015-06-01 Pathology versus molecular genetics: (re)defining the spectrum of Alport syndrome Miner, Jeffrey H. Kidney Int Article Next generation sequencing applied to families with glomerular disease has been instrumental in identifying new genes and pathways involved in podocyte homeostasis. Malone et al. performed sequencing on 70 families with FSGS and discovered that 10% had variants in surprising “old” genes, COL4A3 and COL4A4, which are involved in Alport syndrome and thin basement membrane nephropathy. These data show that a subset of renal manifestations associated with COL4A3 or COL4A4 variants cannot be distinguished from FSGS by clinical data or by histopathology. Thus, a diagnosis of FSGS may sometimes fall within the spectrum of Alport syndrome. 2014-12 /pmc/articles/PMC4246419/ /pubmed/25427084 http://dx.doi.org/10.1038/ki.2014.326 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Miner, Jeffrey H.
Pathology versus molecular genetics: (re)defining the spectrum of Alport syndrome
title Pathology versus molecular genetics: (re)defining the spectrum of Alport syndrome
title_full Pathology versus molecular genetics: (re)defining the spectrum of Alport syndrome
title_fullStr Pathology versus molecular genetics: (re)defining the spectrum of Alport syndrome
title_full_unstemmed Pathology versus molecular genetics: (re)defining the spectrum of Alport syndrome
title_short Pathology versus molecular genetics: (re)defining the spectrum of Alport syndrome
title_sort pathology versus molecular genetics: (re)defining the spectrum of alport syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246419/
https://www.ncbi.nlm.nih.gov/pubmed/25427084
http://dx.doi.org/10.1038/ki.2014.326
work_keys_str_mv AT minerjeffreyh pathologyversusmoleculargeneticsredefiningthespectrumofalportsyndrome